dc.contributor.author | Gleeson, M | |
dc.contributor.author | Hawkes, EA | |
dc.contributor.author | Cunningham, D | |
dc.contributor.author | Chadwick, N | |
dc.contributor.author | Counsell, N | |
dc.contributor.author | Lawrie, A | |
dc.contributor.author | Jack, A | |
dc.contributor.author | Smith, P | |
dc.contributor.author | Mouncey, P | |
dc.contributor.author | Pocock, C | |
dc.contributor.author | Ardeshna, KM | |
dc.contributor.author | Radford, J | |
dc.contributor.author | McMillan, A | |
dc.contributor.author | Davies, J | |
dc.contributor.author | Turner, D | |
dc.contributor.author | Kruger, A | |
dc.contributor.author | Johnson, PWM | |
dc.contributor.author | Gambell, J | |
dc.contributor.author | Linch, D | |
dc.date.accessioned | 2017-07-13T13:23:49Z | |
dc.date.issued | 2016-11 | |
dc.identifier.citation | British journal of haematology, 2016, 175 (4), pp. 668 - 672 | |
dc.identifier.issn | 0007-1048 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/694 | |
dc.identifier.eissn | 1365-2141 | |
dc.identifier.doi | 10.1111/bjh.14287 | |
dc.description.abstract | We performed a subgroup analysis of the phase III UK National Cancer Research Institute R-CHOP-14 versus R-CHOP-21 (two- versus three-weekly rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) trial to evaluate the outcomes for 50 patients with World Health Organization 2008 classified primary mediastinal B-cell lymphoma identified from the trial database. At a median follow-up of 7·2 years the 5-year progression-free survival and overall survival was 79·8% and 83·8%, respectively. An exploratory analysis raised the possibility of a better outcome in those who received R-CHOP-14 and time intensification may still, in the rituximab era, merit testing in a randomised trial in this subgroup of patients. | |
dc.format | Print-Electronic | |
dc.format.extent | 668 - 672 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.subject | Humans | |
dc.subject | Lymphoma, B-Cell | |
dc.subject | Mediastinal Neoplasms | |
dc.subject | Cyclophosphamide | |
dc.subject | Vincristine | |
dc.subject | Doxorubicin | |
dc.subject | Prednisone | |
dc.subject | Antineoplastic Combined Chemotherapy Protocols | |
dc.subject | Neoplasm Staging | |
dc.subject | Prognosis | |
dc.subject | Treatment Outcome | |
dc.subject | Tumor Burden | |
dc.subject | Proportional Hazards Models | |
dc.subject | Adult | |
dc.subject | Aged | |
dc.subject | Middle Aged | |
dc.subject | Female | |
dc.subject | Male | |
dc.subject | Clinical Trials, Phase III as Topic | |
dc.subject | Young Adult | |
dc.subject | Antibodies, Monoclonal, Murine-Derived | |
dc.subject | Multimodal Imaging | |
dc.subject | Rituximab | |
dc.title | Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2016-06-22 | |
rioxxterms.versionofrecord | 10.1111/bjh.14287 | |
rioxxterms.licenseref.startdate | 2016-11 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | British journal of haematology | |
pubs.issue | 4 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.volume | 175 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Medicine (RMH Smith Cunningham) | en_US |
dc.contributor.icrauthor | Cunningham, David | en |